Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TCR2 THERAPEUTICS INC.

(TCRR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TCR2 Therapeutics : HC Wainwright Adjusts TCR2 Therapeutics' Price Target to $25 from $37, Keeps Buy Rating

09/20/2021 | 11:20am EST


© MT Newswires 2021
All news about TCR2 THERAPEUTICS INC.
11/22TCR2 Therapeutics Inc. Announces Resignation of Mayur Somaiya, Effective December 10, 2..
CI
11/11Tcr-2 therapeutics reports third quarter 2021 financial results and provides corporate ..
AQ
11/10TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/10TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
PU
11/10TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
AQ
11/10TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/01TCR2 Therapeutics Announces Expansion of U.S. Manufacturing Capacity - Form 8-K
PU
11/01TCR2 THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, Financial Stat..
AQ
11/01TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity
AQ
11/01Tcr2 Therapeutics Inc. Announces Expansion of U.S. Manufacturing Capacity
CI
More news
Analyst Recommendations on TCR2 THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -100,0 M - -
Net cash 2021 246 M - -
P/E ratio 2021 -1,89x
Yield 2021 -
Capitalization 191 M 191 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 164
Free-Float 96,4%
Chart TCR2 THERAPEUTICS INC.
Duration : Period :
TCR2 Therapeutics Inc. Technical Analysis Chart | TCRR | US87808K1060 | MarketScreener
Technical analysis trends TCR2 THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 5,01 $
Average target price 24,90 $
Spread / Average Target 397%
EPS Revisions
Managers and Directors
Garry E. Menzel President, Chief Executive Officer & Director
Mayur Ian Somaiya Chief Financial Officer
Ansbert K. Gadicke Chairman
Robert Hofmeister Chief Scientific Officer
Alfonso Quintás-Cardama Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TCR2 THERAPEUTICS INC.-83.09%200
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745